January 30th 2023
Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.
January 21st 2023
POINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerJanuary 15th 2018
ASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerJanuary 15th 2018
Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
Proposed Liver Debulking Criteria for PNETs Could Improve SurvivalNovember 16th 2017
Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.
Pancreatic Neuroendocrine Tumors: State-of-the-Art Diagnosis and ManagementOctober 15th 2017
In this review, we focus on the treatment of well-differentiated early and metastatic PNETs, emphasizing current controversies, recent advances in therapy, and the multidisciplinary approach required for optimal treatment.
Current Pancreatic Cancer Guidelines Miss Targetable MutationsAugust 10th 2017
Germline mutations in pancreatic cancer susceptibility genes were commonly identified in a group of patients with pancreatic cancer who did not report a significant family history of cancer, according to the results of a single-center study.
New Treatment Options and Management Considerations in Borderline Resectable Pancreatic CancerJune 15th 2017
In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.